Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen Biosimilars Game On: Filing Chases AbbVie's Humira

This article was originally published in Scrip

Executive Summary

After being the company whose products have been in hot pursuit by makers of biosimilars, Amgen Inc. is seeking to market one of its own, ABP 501, a biosimilar version of AbbVie Inc.'s Humira (adalimumab) – aiming to take a bite out of the nearly $13bn in annual sales the latter firm brings in for its tumor necrosis factor (TNF) blocker.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC063809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel